Profile picture of medscape.com
Get expert insight on how to develop a transition of care plan for patients with spinal muscular atrophy moving from pediatric to adult care ... Show more
Profile picture of Reuters
Sarepta defeats Regenxbio, UPenn patent lawsuit over muscular dystrophy treatment
reuters.com/legal/litigation/sarepta-defeats-regenxbio-upenn-patent-lawsuit-over-muscular-dystrophy-treatment-2024-01-05/
Sarepta defeats Regenxbio, UPenn patent lawsuit over muscular dystrophy ...
Profile picture of Forbes
Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, joined Alex Knapp to discuss innovation in detecting ... Show more
Profile picture of Bloomberg
Sarepta (SRPT) to Seek Approval for DMD Therapy Even After Drug Trial Failed: Normally when a drug fails to show a clear effect in a final-stage trial ...
bloomberg.com/news/articles/2023-10-31/after-drug-trial-fizzles-sarepta-still-seeks-broader-approval
Sarepta (SRPT) to Seek Approval for DMD Therapy Even After Drug Trial ...
Profile picture of Investor's Business Daily
Sarepta Crashes 45% After Its Gene Therapy Flops Its Biggest Test: Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey ...
investors.com/news/technology/srpt-stock-halted-after-sarepta-unveils-mixed-results-for-duchenne-gene-therapy/
Sarepta Crashes 45% After Its Gene Therapy Flops Its Biggest Test
Profile picture of CNBC
These insiders were big buyers this week, including in one beaten-up biotech: CNBC Pro screened for the five U.S. companies with the biggest insider buying over ...
cnbc.com/2023/11/10/these-insiders-were-big-buyers-this-week-including-in-one-beaten-up-biotech.html
These insiders were big buyers this week, including in one beaten-up ...
Profile picture of CNBC
Beware these companies due to report earnings that have negative profit momentum: Analysts have been cutting earnings estimates for these four stocks ahead of ...
cnbc.com/2023/11/09/beware-these-companies-due-to-report-but-that-have-negative-momentum.html
Beware these companies due to report earnings that have negative profit ...
Profile picture of Investor's Business Daily
Biotech Stocks Near An Inflection Point In Gene Therapy: The big names behind biotech stocks want to cure diseases, not just treat them. Gene therapy drugs are ...
investors.com/news/technology/biotech-stocks-near-a-significant-inflection-point-in-gene-therapy-but-watch-your-wallet/
Biotech Stocks Near An Inflection Point In Gene Therapy
Profile picture of PBS
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young children
pbs.org/newshour/health/first-gene-therapy-for-deadly-form-of-muscular-dystrophy-gets-fda-approval-for-young-kids
First gene therapy for deadly form of muscular dystrophy gets FDA approval ...
Quick Glance: FDA Approves Sarepta's Gene Therapy for Rare Muscular Dystrophy
  • The US health regulator has granted accelerated approval to Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD).

  • Initially seeking approval for DMD patients who can walk.

  • Sarepta's gene therapy was able to produce a mini version of the dystrophin protein, but did not improve patient clinical outcomes.

  • Approval for Sarepta's treatment could open doors for more effective gene therapies.
Profile picture of The Wall Street Journal
First Gene Therapy for Muscular Dystrophy Approved: The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder ...
wsj.com/articles/first-gene-therapy-for-muscular-dystrophy-approved-34860988
First Gene Therapy for Muscular Dystrophy Approved
Profile picture of Reuters
Sarepta surges after FDA panel backs Duchenne gene therapy: Shares of Sarepta Therapeutics (SRPT.O) jumped 25% on Monday as a backing by the U.S ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-surges-after-fda-panel-backs-duchenne-gene-therapy-2023-05-15/
Sarepta surges after FDA panel backs Duchenne gene therapy
Profile picture of Bloomberg
Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut: Accelerated approvals have helped get promising therapies to market fast — but ...
bloomberg.com/news/articles/2023-05-14/fda-fast-tracked-drugs-make-companies-billions-on-unproven-claims
Drug Companies Are Minting Billions on Unproven Treatments With FDA ...
Profile picture of NPR
FDA advisers narrowly back first gene therapy for muscular dystrophy: A panel of experts voted 8-6 in favor of Food and Drug Administration approval of the first ...
npr.org/sections/health-shots/2023/05/12/1175852294/fda-advisers-narrowly-back-first-gene-therapy-for-muscular-dystrophy
FDA advisers narrowly back first gene therapy for muscular dystrophy
Profile picture of CNN.com
FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease
cnn.com/2023/05/12/health/duchenne-muscular-dystrophy-therapy-fda/
FDA advisers narrowly vote in favor of experimental gene therapy for rare ...
Profile picture of Reuters
Sarepta drops as report says FDA almost rejected under-review gene therapy: Sarepta Therapeutics Inc's shares (SRPT.O) fell more than 6% on Thursday as Stat News ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-shares-drop-report-says-fda-almost-rejected-under-review-gene-therapy-2023-04-13/
Sarepta drops as report says FDA almost rejected under-review gene therapy
Profile picture of NPR
Gene therapy for muscular dystrophy stirs hopes and controversy: The FDA is considering greenlighting the experimental treatment under its accelerated approvals ...
npr.org/sections/health-shots/2023/05/02/1171357002/gene-therapy-for-muscular-dystrophy-stirs-hopes-and-controversy
Gene therapy for muscular dystrophy stirs hopes and controversy
Profile picture of CNBC
Here are Tuesday's biggest analyst calls: Apple, Amazon, Boeing, Chipotle, Rivian, Etsy, Exxon & more
cnbc.com/2023/04/04/tuesdays-top-wall-street-analyst-calls-include-xom-and-etsy.html
Here are Tuesday's biggest analyst calls: Apple, Amazon, Boeing, Chipotle ...
Profile picture of CNBC
Here are Wednesday's biggest analyst calls: Apple, Procter & Gamble, Tesla, Spotify, AbbVie & more
cnbc.com/2023/03/01/wall-streets-top-analyst-calls-on-wednesday-include-apple-spotify.html
Here are Wednesday's biggest analyst calls: Apple, Procter & Gamble, Tesla ...
Profile picture of CNBC
Citi says the recent sell-off in this biotech stock is 'overdone,' predicts shares can rally 30% from here
cnbc.com/2023/04/04/citi-says-the-recent-selloff-in-this-biotech-stock-is-overdone.html
Citi says the recent sell-off in this biotech stock is 'overdone ...
Profile picture of Investor's Business Daily
Sarepta Breaks Out As FDA Smooths The Path For Its Gene Therapy: Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy ...
investors.com/news/technology/srpt-stock-breaks-out-as-fda-smooths-the-path-for-its-gene-therapy/
Sarepta Breaks Out As FDA Smooths The Path For Its Gene Therapy
Profile picture of CNBC
Here are Thursday's biggest analyst calls: Apple, GameStop, First Solar, Boeing, Moderna & more
cnbc.com/2022/09/08/thursday-street-calls-apple-gamestop-first-solar-boeing-moderna-.html
Here are Thursday's biggest analyst calls: Apple, GameStop, First Solar ...
Profile picture of BÖRSE ONLINE
Ray Dalio on a buying spree - he bought these three stocks: Hedge fund manager legend Ray Dalio has been on a buying spree. But which stocks are particularly ...
boerse-online.de/nachrichten/aktien/ray-dalio-auf-einkaufstour-diese-drei-aktien-hat-er-gekauft-1031695286
Ray Dalio on a buying spree - he bought these three stocks
Profile picture of CNBC
Wall Street pros say these small caps are good buys as recession looms — BofA gives one 40% upside
cnbc.com/2022/08/03/wall-street-small-cap-stocks-that-could-outperform-in-a-recession.html
Wall Street pros say these small caps are good buys as recession looms — ...
Profile picture of CNBC
Stocks making the biggest moves after hours: FedEx, Sarepta Therapeutics and more
cnbc.com/2022/06/23/stocks-moving-after-hours-fedex-sarepta-therapeutics-and-more.html
Stocks making the biggest moves after hours: FedEx, Sarepta Therapeutics ...